# Study to Evaluate Safety and PK/PD of DA-3091 in Healthy Male Subjects

> **NCT01156779** · PHASE1 · COMPLETED · sponsor: **Dong-A Pharmaceutical Co., Ltd.** · enrollment: 31 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** SR-exenatide

## Key facts

- **NCT ID:** NCT01156779
- **Lead sponsor:** Dong-A Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2012-04
- **Final completion:** —
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2013-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01156779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01156779, "Study to Evaluate Safety and PK/PD of DA-3091 in Healthy Male Subjects". Retrieved via MORVS 2026-10-10 from https://api.morvs.ai/clinical/NCT01156779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*